彩色多普勒超声引导射频消融治疗肝硬化合并小肝癌的疗效观察

目的观察彩色多普勒超声引导下,射频消融治疗肝硬化合并小肝癌患者的临床疗效。方法将120例合并肝硬化的小肝癌患者采用超声引导射频消融治疗,观察其术后近、远期疗效及生存率。结果 120例患者共165个肿瘤,首次完全消融达到80.0%,术后第1、3、5年的总体无瘤生存率分别为80.0%、32.5%、30.0%。肿瘤直径≤3 cm组和>3 cm组比较,≤3 cm组近期疗效优于>3 cm组。结论彩色多普勒超声引导射频消融治疗肝硬化合并小肝癌治疗效果好,对肝功能影响小,并发症少。     

99Tc^m-MDP骨显像评估脊柱骨样骨瘤及成骨细胞瘤射频消融效果

目的探讨99Tcm-亚甲基二磷酸盐骨显像对脊柱骨样骨瘤和成骨细胞瘤射频消融疗效评估的价值。资料与方法回顾性收集行射频消融的7例脊柱骨样骨瘤及成骨细胞瘤患者的影像学及临床资料,分析骨显像、CT表现与患者症状、随访结果的关系。结果7例患者(其中骨样骨瘤4例,成骨细胞瘤3例)接受8次射频消融。治疗后2例无疼痛复发,第3、6个月骨显像呈轻度浓聚,其中1例第3个月CT示病变缩小,第12个月消失。3例第4~5个月疼痛复发,骨显像呈轻度浓聚1例,显著浓聚2例,同期CT示病变较治疗前均无变化,继续随访患者疼痛消失。2例射频消融后仍有间断轻度疼痛,第9、12个月骨显像均呈显著浓聚,同期CT示病变缩小1例,增大1例,患者后续分别行手术和再次射频消融。结论骨显像能够早期判断骨样骨瘤和成骨细胞瘤射频消融后病变的活性。骨显像轻度浓聚预示病变治愈,显著浓聚提示病变尚存活性,需继续随访。     

术后即时T1加权成像评估肝脏恶性肿瘤热消融术疗效的价值研究北大核心CSCD

目的:探讨术后即时T1WI评估肝脏恶性肿瘤热消融术疗效的临床价值。方法:收集2018年6月—2020年12月长海医院79例接受CT引导下射频消融或微波消融治疗的肝脏恶性肿瘤患者资料。79例均行术前2周磁共振增强扫描、术后即时T1WI平扫及术后1~3个月磁共振增强扫描。对比术后两次检查结果,论证术后即时T1WI评估效能。分析最小消融边界与热消融术疗效之间的关系。采用t检验或Fisher精确检验进行统计学分析。结果:术后即时T1WI评估完全消融率为100%,术后1~3个月MR增强检查评估完全消融率为93.67%,两者差异无统计学意义(P=0.069)。不完全消融组的最小消融边界[(0.132±0.138)cm]明显低于完全消融组的最小消融边界[(0.427±0.260)cm],差异有统计学意义(P=0.015)。结论:术后即时T1WI可以用于早期评估肝脏恶性肿瘤热消融术疗效,对于指导后续治疗方案的制订具有较显著的临床意义。     

复发性小肝癌再次手术与射频消融的临床分析

目的:总结复发性小肝癌的外科治疗方法。方法回顾性分析2005年1月至2008年6月第1次手术后复发的小肝癌35例患者的临床资料,分为再次手术组和射频消融组,比较两组术后3年生存及复发情况。结果再次手术组18例,均行肿瘤局部切除术,射频消融组17例,均行局部射频消融治疗。再次手术组3年无瘤存活率(66.1%,11/18)高于射频消融者(47.1%,8/17)(P<0.05),手术切除肿瘤局部复发率(22.2%,4/18)低于射频消融(35.6%,5/17)(P<0.05),直径<3cm的肿瘤,采用手术或射频消融治疗3年生存率和复发率差异无统计学意义(P>0.05),3～5cm肿瘤采用手术治疗者3年生存率高于射频消融治疗,复发率低于射频消融治疗(均P>0.05)。结论对复发性小肝癌瘤体小于3mm者应根据患者情况并充分考虑患者意愿进行治疗,对肿瘤为者则以手术为宜。     

超声引导下微小乳头状癌射频消融临床应用

目的探讨甲状腺微小乳头状癌患者采用超声引导下射频消融治疗的临床效果。方法收集本院甲状腺微小乳头状癌27例患者,所有患者均于超声引导下进行射频消融治疗。术后对患者进行为期1年的随访观察,经超声检查观察患者治疗后不同时间的消融灶变化、甲状腺实质与颈部淋巴结状况,以评估患者的临床疗效。结果本组27例患者术后均行为期1年的随访观察,超声检查显示患者的结节不断变小,治疗后首月、3月、半年及1年时患者的结节体积缩小率分别为22.22%、51.85%、85.19%、92.59%。治疗3月时消融灶消失者1例,治疗后半年时消融灶消失者2例,治疗后1年时消融灶消失者6例;其中有26例(96.3%)患者首次治疗后就达到了无瘤生存。治疗后1例患者出现局部复发,1例患者出现淋巴结转移,术后均未出现皮肤气道烫伤与喉返神经损伤等严重的并发症。结论甲状腺微小乳头状癌患者采用超声引导下射频消融治疗疗效显著,安全性较好,值得进一步推广。     

射频热凝术和球囊压迫术治疗眼支三叉神经痛的疗效对比

目的 探讨射频热凝术(PRT)和球囊压迫术(PBC)治疗眼支三叉神经痛(TN)的疗效和安全性。方法 回顾性分析2017年11月至2021年7月收治的46例原发性眼支TN患者的临床资料，接受PRT治疗26例(射频组),接受PBC治疗20例(球囊组)。比较两组患者术前、术后3天、3个月疼痛数字评分(NRS)变化并评估安全性。结果 射频组术前、术后3天、3个月NRS评分分别为(6.96±0.66)分、(0.54±0.51)分、(1.58±1.64)分，球囊组术前、术后3天、3个月NRS评分分别为(6.85±0.59)分、(0.15±0.37)分、(0.65±0.75)分。两组患者术后3天、3个月NRS评分均较术前明显下降(P<0.001),射频组术后NRS评分均显著高于球囊组(3天，P=0.006;3个月，P<0.001)。射频组术后出现角膜麻痹2例，余无严重并发症发生。结论 对于眼支TN患者，PBC较PRT疗效更为显著、安全性更高。     

冷极射频消融联合I125粒子植入治疗肺癌20例报告

目的：探讨冷极射频消融联合I125粒子植入术治疗肺癌患者的疗效。方法采用回顾性分析方法,对我院2007年9月至2012年2月采用冷极射频消融联合植入放射性I125粒子治疗的20例肺癌患者的治疗方案、并发症、疗效等临床资料进行分析和评价。结果20例肺癌患者中,病情完全缓解9例（45%）;部分缓解5例（25%）;无变化3例（15%）;进展3例（15%）。20例患者疾病近期控制率85%。结论冷极射频消融联合I125粒子植入是治疗晚期肺癌不能耐受手术或不愿接受手术治疗患者的一种可行方法,两者联合治疗可提高疗效,减轻并发症。     

肺部恶性肿瘤射频消融治疗后CT影像学改变

目的:观察分析肺部恶性肿瘤射频消融治疗后CT影像学改变。方法:搜集因肺部恶性肿瘤行CT引导下射频消融治疗的患者226例(共计消融灶233个),分析评价治疗后病灶CT影像学改变。患者中原发性肺癌201例,肺转移癌25例。接受射频消融的病灶直径1.00～10.60cm,平均(4.36±2.45)cm。平均随访时间13.61个月(1～30个月)。结果:215例患者(95.13%)治疗后立即出现消融灶周围肺组织内毛玻璃样改变,多在1个月内吸收;191患者(84.51%)治疗后肿瘤立即出现增大,127例患者(56.19%)出现消融灶内多发小空泡形成。术后51例患者(22.57%)出现空洞,恶性胸水多发生在治疗3个月以后。121例患者(65.05%)在术后第一个月随访时胸部CT提示病灶有增大,46.15%和50.89%的患者在3个月及6个月复查时病灶缩小,之后这一比例开始降低,至12个月时,只有33.64%的患者病灶较上一次评估时缩小,到24个月时这一比例降低到4.35%。结论:病变周围的毛玻璃样改变、空洞形成、多发小空泡形成和胸膜改变是射频消融后最常见的CT改变。体积较大的病灶更可能出现空洞改变,射频消融术后1个月内病灶多出现增大表现,治疗后6个月是病灶缩小最明显的时期,6个月后出现的病灶较上一评估周期增大提示患者肿瘤进展。CT是射频术后疗效评估的有效手段之一。     

C臂CT引导下经皮穿刺射频消融术治疗原发性肝癌的临床应用

目的探讨C臂CT(CBCT)引导下经皮穿刺射频消融术治疗原发性肝癌的应用价值。方法选取322例原发性肝癌患者共351个病灶,行射频消融治疗378例次。137例患者在螺旋CT(Spiral Computed Tomograph, SCT)引导下行射频消融165例次(SCT组),185例患者在CBCT引导下行射频消融213例次(CBCT组)。结果手术技术成功率为100%。术后1个月疗效评估,SCT组与CBCT组临床缓解率分别为97.0%(133/137)、96.2%(177/185)。术后总死亡率0.31%(1/322),总并发症发生率为4.1%(15/378),其中SCT组为10.9%(18/165),CBCT组为2.3%(5/213),两者比较有显著性差异(χ~2=11.93,P0.05)。结论 CBCT引导下经皮穿刺射频消融术治疗原发性肝癌具有可行性和安全性,优点是实时监测、定位准确、可以多角度、不受其他脏器的干扰、时间短。缺点是术者要直接接触射线。没有碘油沉积或没有明确标记显示不清的病灶,则需结合术前CT或MRI结果准确定位。     

低温等离子射频消融治疗下颈椎椎间盘源性眩晕的疗效

目的 探讨低温等离子射频消融术治疗下颈椎椎间盘源性眩晕的临床疗效.方法 选取2017-03至2018-06解放军总医院第三医学中心脊柱外科收治的78例颈椎间盘源性眩晕患者,于C形臂X线机引导下行低温等离子射频消融治疗,观察患者术后头晕改善情况.采用0-100视觉模拟评分法和眩晕障碍量表评估眩晕程度变化,采用改良MacN...     

Injectable polymer depot combined with radiofrequency ablation for treatment of experimental carcinoma in rat

OBJECTIVE: The purpose of this study was to investigate whether an intralesional chemotherapy depot with or without a chemosensitizer could improve the efficacy of radiofrequency (RF) ablation in treatment of experimental carcinoma in rats. MATERIALS AND METHODS: Eighteen BD-IX rats were inoculated with bilateral subcutaneous tumors via injection of DHD/K12TRb rat colorectal carcinoma cells in suspension. Four weeks after inoculation, one tumor in each rat was treated with RF ablation at 80 degrees C for 2 minutes and the other with RF ablation followed by intralesional chemotherapy with carboplatin. The drug was administered via 2 different in situ-forming poly(D,L-lactide-coglycolide) (PLGA) depot formulations either with or without a chemosensitizer. Treatment efficacy was assessed by comparing the change in tumor diameter compared with control, percent of coagulation necrosis and a rating of treatment completeness. RESULTS: Tumors treated with ablation and carboplatin + sensitizer (n = 9) showed a diameter decrease of 49.4 +/- 24.5% at the end point relative to ablation control, while those treated with ablation and carboplatin only (n = 8) showed a 7.1 +/- 12.6% decrease. Use of sensitizer also showed increased tissue necrosis (81.9 +/- 9.7% compared with 68.7 +/- 26.7% for ablation only) and double the number of complete treatments (6/9 or 66.7%) compared with ablation control (3/9 or 33.3%). CONCLUSIONS: From these results, we conclude that intralesional administration of a carboplatin and sensitizer-loaded polymer depot after RF ablation has the potential to improve the outcome of ablation by increasing effectiveness of local adjuvant chemotherapy in preventing progression of tumor unaffected by the ablation treatment.     

Percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of 80 patients treated with two consecutive sessions

This study investigated the reasons for some patients requiring two consecutive sessions of percutaneous radiofrequency (RF) ablation of hepatocellular carcinoma (HCC). We reviewed our database of 1,179 patients (1,624 treatments) with HCCs treated by percutaneous ultrasound (US)-guided RF ablation over 6 years. We retrospectively evaluated 80 patients who required a second session after the first session. The medical records and follow-up CTs were studied. We assessed the reasons for the second session and the patient outcomes. A second session was required in 80 (4.8%) out of 1,642 treatments of percutaneous RF ablation for HCC. The reason for the second session included technical failure related to the patient or the procedure (n=26), technical failure due to residual (n=40), newly detected (n=11) or missed (n=3) tumors found at the immediate follow-up CT. All patients were retreated with a second RFA session the next day. Seventy-five (93%) of 80 patients achieved complete ablation after the second session. The remaining five patients were treated by TACE (n=1), additional RFA (as second treatment at next admission) (n=3), or were lost to follow-up (n=1). After 1 month follow-up, 72 patients (96%) showed complete ablation after the second session. The interventional oncologist should understand the technical reasons for a patient requiring a second session of RF ablation when providing treatment for HCCs and perform careful pre-procedural planning to minimize the need for multi-session procedures.     

Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success

OBJECTIVE: The objective of our study was to evaluate the success rate for radiofrequency ablation of renal tumors and to determine the risk of serious complications. CONCLUSION: No serious complications occurred after 27 CT-guided radiofrequency ablation sessions in 22 patients. In total, no residual tumor was detected on follow-up contrast-enhanced CT or MRI 1-35 months (mean, 7 months) after final tumor ablation in 20 (91%) of 22 patients. Two patients with residual viable tumor deferred further treatment. Complete tumor ablation was achieved after a single treatment session in 83% of patients, and in 8% of patients after subsequent ablation sessions. Size was the major determinant for achieving tumor eradication with a single session of ablation, with all 11 tumors 3 cm or smaller being completely ablated after one session. Tumor location, histology, and the presence of renal disease did not correlate with treatment success. Contrast-enhanced CT performed immediately after ablation is reliable to exclude residual viable tumor. CT-guided radiofrequency ablation of renal tumors is safe and has a high rate of success in the treatment of small renal tumors, with no evidence of recurrence at midterm follow-up of treated patients.     

Using multidetector CT for preoperative vascular evaluation of liver neoplasms: technique and results

OBJECTIVE: We evaluated the feasibility, tolerance, and efficacy of percutaneous hepatic vein or segmental portal branch balloon occlusion during radiofrequency ablation of hepatic malignancies. SUBJECTS AND METHODS: Ten tumors were treated by percutaneous radiofrequency ablation during balloon occlusion of a hepatic vein (n = 8) or a segmental portal branch (n = 2). Venous occlusion was undertaken because the tumor was in contact with a hepatic vein (n = 3) or a portal branch (n = 1); because the tumor exceeded 35 mm in width (mean, 44 mm), which was considered the maximum size amenable to ablation in a single session (n = 2); or because of both large size and contact with a hepatic vein (n = 3) or a portal branch (n = 1). RESULTS: Vascular occlusion was always technically possible. Radiofrequency was delivered to one to three locations (mean, 1.9 locations) with a cluster electrode. The largest axis of radiofrequency-induced lesions after ablation with the cluster needle-between 42 and 51 mm (mean, 49 mm)-was always larger than the targeted tumor. These sizes were statistically larger than in a matched control group of patients who underwent radiofrequency ablation without vascular occlusion (p < 0.0003). After a mean follow-up of 12.6 months, CT and MR imaging revealed complete destruction of nine tumors after a single radiofrequency ablation treatment; one tumor required three treatments to achieve ablation. Five patients are tumor-free 12-18 months (mean, 14.4 months) after the first radiofrequency ablation treatment, and five developed new liver metastases. CONCLUSION: Temporary hepatic vein or portal branch occlusion during radiofrequency ablation can safely facilitate the treatment of large tumors or tumors in contact with the walls of large vessels.     

Imaging-guided percutaneous radiofrequency ablation of solid renal masses: techniques and outcomes of 38 treatment sessions in 32 consecutive patients

OBJECTIVE: The purpose of this study was to describe the treatment techniques and results of 38 consecutive imaging-guided percutaneous radiofrequency ablations of solid renal masses performed in 32 patients. MATERIALS AND METHODS: Solid renal masses in 32 patients underwent 38 treatment sessions using imaging-guided percutaneous radiofrequency ablation. During 36 sessions, radiofrequency ablation was performed using CT guidance, and two, using sonographic guidance. The average patient age was 76 years (range, 52-87 years), and the average renal mass size was 2.6 cm (range, 1-5 cm). The average number of radiofrequency treatments per solid mass at each session was 2.4 (range, 1-6 treatments), and the average time per treatment was 9.2 min (range, 3-14 min). A single electrode was used in 12 sessions, and a cluster electrode was used in 26 sessions. The average follow-up time was 9 months (range, 1-36 months). RESULTS: Twenty-six of 32 patients had successful treatment of the solid renal mass using percutaneous imaging-guided radiofrequency ablation after one treatment session. Successful treatment was defined as lack of enhancement of the treated region on follow-up CT. Six of 32 patients had residual enhancing tissue after the first treatment session and returned for a second session. Five of these six retreatments were successful. Masses requiring a second treatment session were significantly larger than masses treated in a single session (3.5 vs 2.4 cm, respectively; p = 0.0013). Two patients had perinephric hematomas (which did not require transfusion), and one patient developed a 5-mm skin metastasis at the electrode insertion site, which was resected without recurrence. CONCLUSION: Percutaneous imaging-guided radiofrequency ablation shows promise in the treatment of solid renal malignancies.     

Percutaneous radiofrequency ablation for unresectable large hepatic tumours during hepatic blood flow occlusion in four patients

AIM: To evaluate percutaneous radiofrequency (RF) ablation therapy for unresectable large hepatic tumours combined with regional interruption of hepatic blood flow, and to assess the safety and efficacy of this procedure. MATERIALS AND METHODS: Four patients with hepatic tumours were enrolled in this study. Patients were treated by a single session of RF ablation during occlusion of both hepatic artery and hepatic vein. Tumour size ranged from 45-57 mm (mean 50.2 mm). Initial therapeutic efficacy was evaluated with helical computed tomography (CT) performed within 9 days after the treatment. CT or magnetic resonance imaging (MRI) was performed every 2-3 months thereafter. RESULTS: The largest axis of coagulated lesions after the ablation was 50-60 mm (mean 56.5 mm) in diameter. The ablation therapy was considered complete in three patients; after a mean follow-up of 12.7 months, CT and MRI revealed complete destruction of their tumours. One patient required further treatment. No severe complications occurred. CONCLUSION: Although further studies are needed, in this limited clinical trial a local ablation area exceeding 50 mm in diameter was achieved safely.     

Assessment of cerebral microembolism during percutaneous radiofrequency ablation of lung tumors using diffusion-weighted imaging

OBJECTIVE: It is well known that radiofrequency ablation generates microbubbles in the liver. We hypothesized that microbubbles generated during percutaneous radiofrequency ablation of lung tumors flow into the pulmonary veins and are distributed to the systemic arteries, as with radiofrequency ablation of liver tumors. To assess the risk of cerebral infarction during radiofrequency ablation of lung tumors, we performed diffusion-weighted imaging and, if possible, monitored microemboli in the carotid artery during radiofrequency ablation. SUBJECTS AND METHODS: We prospectively studied 20 patients (19 men and one woman) who underwent radiofrequency ablation of lung tumors. Pre- and postoperative MRI examinations were performed in all 20 patients, and during 17 radiofrequency ablation sessions, sonography was used to monitor whether microemboli were generated. RESULTS: Radiofrequency ablation was technically feasible for the treatment of selected pulmonary tumors. Microemboli, which were believed to represent microbubbles, were seen on sonography during three of the 17 radiofrequency ablation sessions. They were rarely observed when a lung tumor was small, the treatment session was brief, and the radiofrequency emission power was low. No new area of abnormal intensity was seen on postoperative MRI in all 20 patients. Although the microemboli were observed, MRI could not confirm infarction. CONCLUSION: We concluded that cerebral infarction as a result of microbubbles generated during radiofrequency ablation of lung tumors has a low possibility of becoming a clinical problem.     

Power rolloff during interactive radiofrequency ablation can enhance necrosis when treating hepatocellular carcinoma

OBJECTIVE: The purpose of this study was to compare the efficacy between standard and interactive radiofrequency ablation for treatment of hepatocellular carcinoma. SUBJECTS AND METHODS: Of 97 patients with 112 nodular hepatocellular carcinomas, 59 hepatocellular carcinomas were ablated using a standard algorithm and 53 hepatocellular carcinomas, using an interactive algorithm. For the procedure using the interactive algorithm, the electrode's array was partially retracted or fully deployed depending on the change of impedance. Complete tumor necrosis was defined as the lack of enhancement on single-detector helical CT at least 4 months after the last radiofrequency ablation. RESULTS: Complete necrosis was achieved in 101 (90%) of 112 hepatocellular carcinomas, with complete necrosis being achieved more frequently in hepatocellular carcinomas undergoing interactive ablation (96%) than standard ablation (85%) (p = 0.034). Power rolloff (a clinical end point in which power decreases as impedance increases) occurred in all of the 53 hepatocellular carcinomas that underwent interactive ablation, whereas power rolloff occurred in 48 (81%) of the 59 hepatocellular carcinomas that underwent standard ablation (p = 0.00053). Complete necrosis occurred more frequently when rolloff was achieved (96%) than without rolloff (36%) (p < 0.0001). Multivariate analysis determined that power rolloff was an independent factor in achieving complete necrosis of hepatocellular carcinomas (p < 0.0001). CONCLUSION: The use of interactive radiofrequency ablation increased the frequency of power rolloff and the rate of complete necrosis in the treatment of hepatocellular carcinoma. Power rolloff was a significant determinant of whether complete necrosis was achieved in hepatocellular carcinomas treated with radiofrequency ablation.     

肝动脉化疗栓塞术联合CT引导下射频消融治疗大肝癌的疗效和安全性

 目的 评价肝动脉化疗栓塞术(transcatheter arterial chemoembolization, TACE)联合CT引导下经皮穿刺射频消融治疗大肝癌的疗效及安全性。方法 回顾性分析52例经穿刺病理或影像学诊断的大肝癌患者临床资料,患者均先行1次TACE术,术后2周复查增强CT,对碘油沉积欠缺的区域在CT导向下进行射频消融治疗,术后复查甲胎蛋白(AFP)、增强MRI或CT评价肿瘤体积缩小及坏死情况,随访时间为12个月。结果 52例 (56个病灶)手术均获得成功。TACE术前病灶最大径为(12.7±2.7)cm,射频术后1个月病灶最大径为(6.1±1.9)cm,肿瘤大小较术前均有不同程度缩小(t=14.416,P<0.05)。TACE术前AFP值为(4156±689)ng/ml,射频术后1个月为(256±178)ng/ml,AFP值明显下降(t=39.485,P<0.05)。其中完全消融(CR)26例,大部分消融(PR)21例,稳定(SD)4例,进展(PD)1例,总体有效率为90.4%,12个月生存率为92.3%。结论 TACE联合CT导向下射频消融治疗大肝癌是一种安全、有效、微创的治疗方法。     

难治性精神病的立体定向多靶点联合损毁治疗

目的:探讨难治性精神病的立体定向技术和多靶点组合的临床疗效。方法:立体定向下经CT、电阻值和微电极电生理核团定位,对160例难治性精神病患者,采用杏仁核、内侧隔区、扣带回等多靶点组合射频热凝治疗。应用多种精神病评定量表在术后6个月对治疗效果进行评定。结果:依据减分率标准,160例中,显著进步84例,进步70例,无变化6例。手术前后量表评分有显著差异(P<0.05)。结论:多靶点组合的立体定向技术是难治性精神病的有效治疗方法之一。